Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol ATXN3 contributors: mct/pgu - updated : 27-06-2018
HGNC name ataxin 3
HGNC id 7106
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • structured N-terminal Josephin domain (JD) , folded N-terminal domain (Josephin domain, residues 1-182)
  • nuclear localization signal (NLS) close to the glutamine tract
  • two ubiquitin-interacting motifs that bind polyubiquilated proteins with a strong preference for chains containing four or more ubiquitins and a polyQ-tract, two contiguous but distinct ubiquitin-binding sites
  • a central flexible region (residues 183-291), a poly-glutamine sequence of variable length
  • C-terminal polyglutamine-containing domain (a polyglutamine stretch encoded by 13 to 36 CAG repeats), inhibiting coactivator-dependent transcription and required for binding coactivators, short C-terminal flexible region
  • mono polymer heteromer
    HOMOLOGY
    interspecies ortholog to rattus Atxn3
    ortholog to murine Mjd
    Homologene
    FAMILY
    CATEGORY enzyme , regulatory , signaling neurotransmitter
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm
    intracellular,nucleus,nucleoplasm
    text
  • translocation in the nucleus for formation of intranuclear inclusions (Marinesco body)
  • upon oxidative stress, ATXN3 and FOXO4 translocate to the nucleus
  • basic FUNCTION
  • cysteine-protease associated factor conferring a higher susceptibility to death on cells in the Golgi phase
  • inducing cell death and formation of intranuclear inclusions in neuronal cells
  • playing a role in ubiquitin-dependent pathways and in transcriptional activation
  • histone-binding with two independent transcriptional corepressor activities, transcriptional regulation involving targeting histones, coactivators, and an independent mode of direct repression of transcription
  • monomeric domain which folds into a globular conformation and possesses ubiquitin protease activity
  • involved in regulation of the endoplasmic reticulum-associated degradation pathway by modulating VCP-dependent extraction of proteins from the ER
  • polyubiquitin binding protein with ubiquitin protease activity and is a striking suppressor of polyglutamine neurodegeneration
  • having autoproteolytic activity, sustained by the same residues responsible for the ubiquitin hydrolase activity (autolytic activity may play a role in pathogenesis, as fragments carrying expanded polyglutamines are thought to be significantly more toxic than the whole protein)
  • cleaves ubiquitin chains through its Josephin domain and binds ubiquitin chains through a C-terminal cluster of ubiquitin interaction motifs neighboring the pathogenic polyglutamine tract
  • deubiquitinating enzymes that edits topologically complex chains
  • displays deneddylase activity against a fluorogenic NEDD8 substrate
  • Josephin domain-containing proteins is a novel family of active de-ubiquitination enzymes with wide phylogenic distribution
  • key role of CSNK2A1-mediated phosphorylation of ATXN3 in MJD pathophysiology
  • acts as a polyubiquitin-binding protein, recruiting poly-ubiquitinated substrates through a carboxy-terminal cluster of ubiquitin interaction motifs
  • cleaves ubiquitin chains through its Josephin domain and thereby facilitates proteasomal degradation
  • plays an important role in regulating the FOXO4-dependent antioxidant stress response via SOD2,suggesting that a decreased antioxidative capacity and increased susceptibility towards oxidative stress contributes to neuronal cell death in MJD
  • UBE2W and ATXN3, participate in initiating, regulating, and terminating the STUB1 ubiquitination cycle
  • potential role of ATXN3 cleavage by calpains in the pathogenesis of MJD
  • plays an important role in regulating the BL2L1-BAX-mediated anti-oxidative response by modulating the interaction between BCL2L1 and BAX
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
  • component of the ubiquitin proteasome system
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • interaction of normal and mutant MJD with the UBL domain of RAD23A, RAD23B
  • VCP through its polyglutamine domain (binding is modulated by the size of the polyglutamine tract)
  • interacting with the major histone acetyltransferases cAMP-response-element binding protein (CREB)-binding protein, p300, and p300/CREB-binding protein-associated factor
  • specific binding of nuclear proteins to the putative core promoter region
  • interacting with UBE4B (thereby mediated its polyubiquitylation)
  • interacts with ubiquitin-proteasome pathway components
  • PSMC5 plays an important role in regulating ataxin-3 degradation by the proteasome
  • molecular interaction between wild-type ataxin-3 and NEDD8
  • functional interaction between ATXN3 and PARK2 (both wild-type and polyQ-expanded mutant ataxin-3 can deubiquitinate parkin, regardless of the lysine residue used to assemble poly-Ub chains) (
  • interacts with the forkhead box O (FOXO) transcription factor FOXO4 and activates the FOXO4-dependent transcription of the manganese superoxide dismutase (SOD2) gene
  • in the nucleus, concomitantly bind to the SOD2 gene promoter and increase the expression of the antioxidant enzyme SOD2
  • opposes PARK2 ubiquitination by regulating the E2 ubiquitin-conjugating enzyme
  • key role of calpain in ATXN3 aggregation, but ggregate formation was dependent on functional Na+ and K+ channels as well as ionotropic and voltage-gated Ca2+ channels
  • required for the efficient recruitment of the neurodegenerative disease-associated protein copper-zinc superoxide dismutase (SOD1) to aggresomes
  • VCP was shown to be an activator specifically of wild-type ATXN3, exhibiting no effect on expanded ATXN3
  • is a substrate of CAPN1 and CAPN2 and these proteases present promising targets for therapeutic intervention
  • plays a protective role against cellular oxidative stress induced by H2O2 in a BCL2L1-dependent manner
  • promotes the interaction between BCL2L1 and BAX, but does not affect the ubiquitination and degradation of BCL2L1
  • VCP-ATXN3 complex is the essential machinery for regulation of RNF8 homeostasis under both physiological and genotoxic conditions
  • VCP stabilizes BECN1 levels by promoting the deubiquitinase activity of ATXN3 towards BECN1
  • cell & other
    REGULATION
    Other regulated by CSNK2A1 (CSNK2A1-dependent phosphorylation controls nuclear localization, inclusion formation and stability of ATXN3)
    ASSOCIATED DISORDERS
    corresponding disease(s) MJD
    Susceptibility
    Variant & Polymorphism other no evidence for an instability predisposing haplotype due to the stretch of polyglutamine
    Candidate gene for therapeutic by ribosome-interacting drugs (to fight the toxicity of polyalanine-frameshifted peptides)
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    neurologyataxia 
    potential therapeutic role of ataxin-3 activity for polyglutamine disorders
    neurologyataxia 
    target for therapeutic by ribosome-interacting drugs (to fight the toxicity of polyalanine-frameshifted peptides)
    cancer  
    targeting ATXN3 may be a promising strategy to radio-sensitise BRCA-deficient cancers
    ANIMAL & CELL MODELS